United Kingdom· GB-APID-42199411000001108
Camzyos 2.5mg capsules
A mavacamten product containing mavacamten, registered in United Kingdom by Bristol-Myers Squibb Pharmaceuticals Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Mavacamten is registered in 15 of 19 countries.
Countries holding a registration under ATC C01EB24 (mavacamten), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Mavacamten · ATC C01EB24
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mavacamten costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mavacamten · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$118.52
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Mavacamten
- Manufacturer
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Country
- United Kingdom (GB)
- ATC code
- C01EB24
- ATC class
- Mavacamten
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05012712800118
- gtin5012712800118
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mavacamten in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCAMZYOSBristol-Myers Squibb Pharma EEIG, Dublin
- CanadaCAMZYOSBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandCamzyos
- SpainCAMZYOS 2,5 MG CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- FinlandCAMZYOSBristol-Myers Squibb Pharma EEIG
- FranceCAMZYOS 2,5 mg, géluleBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandCamzyos 2.5 mg Capsule hardBristol-Myers Squibb Pharma EEIG
- IcelandCamzyosBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Camzyos
- Liechtenstein · Camzyos
- Norway · Camzyos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f883763-25a3-4c29-af64-77cc2f5db90c GET /v1/drugs/3f883763-25a3-4c29-af64-77cc2f5db90c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42199411000001108",
"desc": "Camzyos 2.5mg capsules (Bristol-Myers Squibb Pharmaceuticals Ltd)",
"form": "Oral capsule",
"vpid": "42202011000001106",
"source": "dmd",
"vtm_id": "42201711000001101",
"strength": "2.5 mg",
"substance": "Mavacamten",
"ingredient": "Mavacamten",
"supplier_code": "3145301000001104"
}See everything about mavacamten.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.